Kelly Rauber
Responsable des Ressources Humaines chez VERA THERAPEUTICS, INC.
Profil
Kelly Rauber is currently the Vice President & Head-Human Resources at Vera Therapeutics, Inc. Prior to this, Ms. Rauber held positions as the Senior Director-Human Resources at Dermira, Inc., Orchard Therapeutics Plc, and Oric Pharmaceuticals, Inc. Ms. Rauber completed their undergraduate degree at Santa Clara University.
Postes actifs de Kelly Rauber
| Sociétés | Poste | Début |
|---|---|---|
| VERA THERAPEUTICS, INC. | Responsable des Ressources Humaines | 01/10/2022 |
Anciens postes connus de Kelly Rauber
| Sociétés | Poste | Fin |
|---|---|---|
| DERMIRA, INC. | Responsable des Ressources Humaines | - |
| ORCHARD THERAPEUTICS PLC | Responsable des Ressources Humaines | - |
| ORIC PHARMACEUTICALS, INC. | Responsable des Ressources Humaines | - |
Formation de Kelly Rauber
| Santa Clara University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
